Dr. Aebi on Adjuvant Chemo in Recurrent Breast Cancer

Stefan Aebi, MD
Published: Thursday, Dec 06, 2012

Stefan Aebi, MD, head of the division of medical oncology at Luzerner Kantonsspital in Luzern, Switzerland, discusses findings from the CALOR trial that examined the administration of adjuvant chemotherapy for women with resected isolated local or regional recurrence (ILRR) of breast cancer that had not developed distant metastasis.

The standard treatment option for patients with ILRR is surgery and radiation therapy, Aebi notes. Prior to this trial, the efficacy of administering adjuvant chemotherapy had not been validated.

In this trial, 162 patients were evenly stratified based on whether they had or had not received prior chemotherapy, their hormone receptor status, and the location of the recurrence. Patients on the investigational arm received 4 courses of the physician's choice of chemotherapy while the control arm received the standard of care.

The trial found that adjuvant chemotherapy reduced the incidence of further relapses and the risk of dying from breast cancer, states Aebi. At a median follow up of 4.9 years, the overall survival rate for patients receiving adjuvant chemotherapy was 88% versus 76% in the control arm (HR = 0.41; P = .02).

<<< View coverage from the 2012 SABCS

Stefan Aebi, MD, head of the division of medical oncology at Luzerner Kantonsspital in Luzern, Switzerland, discusses findings from the CALOR trial that examined the administration of adjuvant chemotherapy for women with resected isolated local or regional recurrence (ILRR) of breast cancer that had not developed distant metastasis.

The standard treatment option for patients with ILRR is surgery and radiation therapy, Aebi notes. Prior to this trial, the efficacy of administering adjuvant chemotherapy had not been validated.

In this trial, 162 patients were evenly stratified based on whether they had or had not received prior chemotherapy, their hormone receptor status, and the location of the recurrence. Patients on the investigational arm received 4 courses of the physician's choice of chemotherapy while the control arm received the standard of care.

The trial found that adjuvant chemotherapy reduced the incidence of further relapses and the risk of dying from breast cancer, states Aebi. At a median follow up of 4.9 years, the overall survival rate for patients receiving adjuvant chemotherapy was 88% versus 76% in the control arm (HR = 0.41; P = .02).

<<< View coverage from the 2012 SABCS


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Interchange™: Translating Research to Inform Changing Paradigms: Assessment of Emerging Immuno-Oncology Strategies and Combinations across Lung, Head and Neck, and Bladder CancersOct 31, 20182.0
Community Practice Connections: Oncology Best Practice™ Targeting Cell Cycle Progression: The Latest Advances on CDK4/6 Inhibition in Metastatic Breast CancerOct 31, 20181.0
Publication Bottom Border
Border Publication
x